Source: Stem Cell Therapeutics Corp.
Posted: February 20, 2008 - 10:32 ET
In an official company news release, Stem Cell Therapeutics Corporation, a biotechnology focused on the development of drug-based therapies to treat central nervous system diseases, reported favorable results from a safety trial of a treatment for ischemic stroke:
" Stem Cell Therapeutics Corp. is pleased to announce favorable results from the investigator led BETAS (Beta-hCG + Erythropoietin in Acute Stroke), Phase IIa, open label, safety trial conducted at the University of California, Irvine and Hoag Presbyterian Memorial Hospital, Newport Beach, CA. This trial is the first to test the safety of NTxTM-265 in patients suffering acute ischemic stroke and to conduct a preliminary assessment of functional recovery in this patient population. Results from the BETAS trial showed no serious adverse events related to NTxTM-265 in the 13 patients enrolled. Of these, 8 patients completed the 90 day assessment term and each of them showed a clinically relevant improvement in their National Institutes of Health Stroke Scale (NIHSS) score of 4 points or greater."
